GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,775.00p
   
  • Change Today:
    -8.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.92m
  • Volume: 9,685,447
  • Market Cap: £73,572m
  • RiskGrade: 129

Sunday newspaper round-up: White Hydrogen, Bank of England, AI

By Alexander Bueso

Date: Sunday 13 Aug 2023

LONDON (ShareCast) - (Sharecast News) - America's Geological survey estimates that if even a small fraction of naturally occurring - and clean or so-called 'white' - hydrogen beneath the earth's surface were recovered, that would last for hundreds of years. Among the backers of the hydrogen industry is Bill Gates, who ploughed $90m into Koloma, a company hunting for natural hydrogen along the US's Midcontinental Rift System. White hydrogen has also been discovered in Europe, in France's Lorraine region. Nonetheless, the true potential of the stuff will hinge on the findings from those early projects, says Philip Ball, research fellow at Keele University. - Guardian
The UK's 'pancake like' economy may fall into a recession induced by the Bank of England's policies, according to its former chief economist, Andy Haldane. "It's stuck. The economy's stuck. In growth terms, it's been treading water for at least a year," he said. "And looking ahead, if you believe the forecasts, it seems set to remain largely stuck for the months and quarters ahead." The country's economy remains the only one out of the G-7 that has yet to recover its pre-pandemic size. In the case of wages, those of younger workers had dropped since 2008 by the most since the nineteenth century. Yet he remained optimistic, pointing out the scope for boosting the size of the overall workforce. - Sunday Telegraph

Artificial Intelligence may dramatically cut the time needed to develop new medicines, GlaxoSmithKline said. The drugmaker had also begun using AI to tailor drugs to patients, thus increasing their effectiveness. It AI hubs are also helping speed up clinical trials. Some stages of trials, such as analysing data, are being sped up by a factor of five. AI is also helping scientists assess hundreds of the potential causes of a disease in the same amount of time previously requierd to study just one cause. - Financial Mail on Sunday

Entain is looking into whether it can claw back tens of millions paid out in bonuses to former bosses as it faces a potential £600m fine from a criminal investigation into its Turkish unit. That would be one of the biggest criminal fines ever levied by the Crown Prosecution Service in the UK's corporate history. HMRC's investigation involved GVC's - Entain's previous name - use of third party suppliers to use third-party suppliers to process payments that in turn allowed GVC to offer online gambling services in Turkey. - The Sunday Times

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,775.00p
Change Today -8.50p
% Change -0.48 %
52 Week High 1,812.50p
52 Week Low 1,316.00p
Volume 9,685,447
Shares Issued 4,144.92m
Market Cap £73,572m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.05% below the market average69.05% below the market average69.05% below the market average69.05% below the market average69.05% below the market average
45.1% below the sector average45.1% below the sector average45.1% below the sector average45.1% below the sector average45.1% below the sector average
Price Trend
47.89% above the market average47.89% above the market average47.89% above the market average47.89% above the market average47.89% above the market average
62.96% above the sector average62.96% above the sector average62.96% above the sector average62.96% above the sector average62.96% above the sector average
Income
2.90% above the market average2.90% above the market average2.90% above the market average2.90% above the market average2.90% above the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
20.71% below the market average20.71% below the market average20.71% below the market average20.71% below the market average20.71% below the market average
29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 16-May-24 22-Feb-24
Paid 11-Jul-24 11-Apr-24
Amount 15.00p 16.00p

Trades for 17-May-2024

Time Volume / Share Price
16:51 423 @ 1,775.00p
16:37 20,200 @ 1,771.97p
16:36 10,580 @ 1,775.00p
16:35 3,357,820 @ 1,775.00p
16:35 2,092 @ 1,775.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page